Диссертация (1139687), страница 32
Текст из файла (страница 32)
Bachmanova. – London: Taylor Francis, 1990. — 339 p.203100. Asha, K. K. Protective effect of taurine on the mitochondria of albino ratsinduced with fulminant hepatic failure / K. K. Asha, K. Devadasan // Biomed PrevNutr.– 2013. – Vol. 3. – N 3 – 279–283.101. Atkins, W. M. Allosteric behavior in cytochrome p450-dependent in vitrodrug-drug interactions: aprospectivebased on conformational dynamics/W. M.
Atkins, R. W. Wang, A. Y. Lu // Chem Res Toxicol. – 2001. – Vol. 14. – P. 338–334.102. Atrakchi, A. H. Interpretation and considerations on the safety evaluationof human drug metabolites / A. H. Atrakchi // Chemical Research in Toxicology. –2009. – Vol. 22. – N 7. – P. 1217–1220.103. Auld, D. S. Bioluminescent Assays for Cytochrome P450 Enzymes /D. S. Auld, H.
Veith, J. J. Cali // Cytochrome P450 protocols, Methods in MolecularBiology, vol. 987 / ed. I. R. Phillips, E. A. Shephard, P. R. Ortiz de Montellano. – 3rded. – Springer Science+Business Media New York, 2013. – Ch. 1. – P. 1–9.104. Baas, B. J. Homotropic cooperativity of monomeric cytochrome P450 3A4in a nanoscale native bilayer environment / B.
J. Baas, I. G. Denisov, S. G. Sligar //Arch Biochem Biophys. – 2004. – Vol. 430. – P. 218–228.105. Bartlett, P. N. Bioelectrochemistry: fundamentals, experimental techniquesand applications / ed. Philip Bartlett. – New York: John Wiley & Sons, Inc., 2008. –494 p.106. Beneficial effects of alpha-lipoic acid and ascorbic acid on endotheliumdependent, nitric oxide-mediated vasodilation in diabetic patients: relation to parametersof oxidative stress / T.
Heitzer [et al.] // Free Radic Biol Med. – 2001. – Vol. 31. – N 1.– P. 53–61.107. Bensoussan, C. Particular ability of cytochrome P450 3A to form inhibitoryP450-iron-metabolitecomplexesuponmetabolicoxidation of aminodrugs/C. Bensoussan, M. Delaforge, D. Mansuy // Biochem Pharmacol. – 1995. –Vol. 49. –P. 591–602.108. Bernhardt R. Cytochromes P450 as versatile biocatalysts / R. Bernhardt //J. Biotechnol. – 2006. – Vol.
124. – N 1. – P. 128–145.204109. Biewenga, G. P. The pharmacology of the antioxidant lipoic acid /G. P. Biewenga, G. R. Haenen, A. Bast // Gen Pharmacol. – 1997. – Vol. 29. – N 3. –P. 315–331.110. Biochemical studies on cytochrome P-450 solubilized from livermicrosomes: partial purification and mechanism of catalysis / M. J. Coon [et al.] // Ann.NY Acad. Sci. –1973.
– Vol. 212. – P. 449–457.111. Birringer, M. Tocopherols are metabolized in HepG2 cells by side chainomega-oxidationandconsecutivebeta-oxidation/M. Birringer,D. Drogan,R. Brigelius-Flohe // Free Radic Biol Med. – 2001. – Vol. 31. – P. 226–232.112. Blake, R. C. II. On the mechanism of action of cytochrome P-450.Evaluation of homolytic and heterolytic mechanisms of oxygen-oxygen bond cleavageduring substrate hydroxylation by peroxides / R.
C. Blake II, M. J. Coon // J. Biol.Chem. – 1981. – Vol. 256. – P. 12127–12133.113. Carr, A. C. Toward a new recommended dietary allowance for vitamin Cbased on antioxidant and health effects in humans / A. C. Carr, B. Frei // Am J ClinNutr. – 1999. – Vol. 69. – N 6. – P. 1086–1107.114. Carreau, J. P. Biosynthesis of lipoic acid via unsaturated fatty acids /J. P. Carreau // Methods Enzymol. – 1979. – Vol. 62. – P. 152–158.115. Characterization of dasatinib and its structural analogs as CYP3A4mechanism-based inactivators and the proposed bioactivation pathways / X.
Li [et al.] //Drug Metab Dispos. – 2009. – Vol. 37 – P. 1242–1250.116. Chaudhary, P. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 byCNS endothelial cells and T cell migration into the spinal cord in experimentalautoimmune encephalomyelitis / P. Chaudhary, G. H. Marracci, D. N. Bourdette // JNeuroimmunol. – 2006. – Vol. 175. – N 1–2. – P. 87–96.117. Cheng, J. W. Updates on Cytochrome P450-Mediated Cardiovascular DrugInteractions / J. W.
Cheng, W. H. Frishman, W. S. Aronow // Dis Mon. – 2010. –Vol. 56. – N 3. – P. 163–179.205118. Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memoryof aged Tg2576 mice / J. F. Quinn [et al.] // Neurobiol Aging. – 2007. – Vol. 28. – N 2.– P. 213–225.119. Collins, R.
The MRC/BHF Heart Protection Study: preliminary results /R. Collins, R. Peto, J. Armitage // Int J Clin Pract. – 2002. – Vol. 56. – N 1. – P. 53–56.120. Common allelic variants of cytochrome P4503A4 and their prevalence indifferent populations / J. K. Lamba [et al.] // Pharmacogenetics. – 2002. – Vol. 12 –P. 121–132.121.
Co-ordinate induction of hepatic mitochondrial and peroxisomal carnitineacyltransferase synthesis by diet and drugs / P. S. Brady [et al.] // Biochem J. – 1989. –Vol. 260. – N 1. – P. 93–100.122. Conformational heterogeneity of cytochrome P450 3A4 revealed by highpressure spectroscopy / D. R. Davydov [et al.] // Biochem Biophys Res Commun. –2003. – Vol.
312 – P. 121–130.123. Conney, A. H. Induction of drug-metabolizing enzymes: path to thediscovery of multiple cytochromes P450 / A. H. Conney // Annu. Rev. Pharmacol.Toxicol. – 2003. – Vol. 43 – P. 1–30.124. Contribution of Itraconazole Metabolites to Inhibition of CYP3A4 In Vivo./ I. E. Templeton [et al.] // Clin Pharmacol Ther.
– 2007. – Vol. 83 – P. 77–85.125. Coon, M. J. Cytochrome P450: nature's most versatile biological catalyst /M. J. Coon // Annu Rev Pharmacol Toxicol. – 2005. – Vol. 45 – P. 1–25.126. Coon, M. J. Enzyme ingenuity in biological oxidations: a trail leading tocytochrome P450 / M. J. Coon // J. Biol. Chem. – 2002. – Vol.
277. – P. 28351–28363.127. Crystal structures of human cytochrome P450 3A4 bound to metyraponeand progesterone. / P. A. Williams [et al.] // Science. – 2004. – Vol. 305. – N 5684. –P. 683–686.128. CYP3A4 active site volume modification by mutagenesis of leucine 211 /S. M.
Fowler [et al.] // Drug Metab Dispos. – 2002. – Vol. 30 – P. 452–456.206129. CYP450 phenotyping and metabolite identification of quinine by accuratemass UPLC-MS analysis: a possible metabolic link to blackwater fever /S. R. Marcsisin [et al.] // Malar J. – 2013. – Vol. 12. – P. 214.130. Cytochrome p450 biosensors – A review / Bistolas, N. [et al.] // Biosens.Bioelectron.
– 2005. – Vol. 20. – P. 2408–2423.131. Cytochrome P450 Enzymes and Electrochemistry: Crosstalk withElectrodes as Redox Partners and Electron Sources / V. V. Shumyantseva [et al.] //Monooxygenase, Peroxidase and Peroxygenase Properties and Mechanisms ofCytochrome P450. Advances in Experimental Medicine and Biology, vol. 851 /E. G. Hrycay, S. M. Bandiera. – Cham: Springer International Publishing Switzerland,2015. – Chap. 9.
– P. 229–246.132. Cytochrome P450 fluorometric substrates: identification of isoformselective probes for rat CYP2D2 and human CYP3A4 / D. M. Stresser [et al.] // DrugMetab Dispos. – 2002. – Vol. 30. – N 7. – P. 845–852.133. Cytochrome P450 oxidase activity and its role in NADPH dependent lipidperoxidation / A. Bast // FEBS Lett. – 1983. – Vol. 151. – N 2. – P. 185–188.134.
Cytochrome P450 regulation by α-tocopherol in Pxr-null and PXRhumanized mice / C. H. Johnson [et al.] // Drug Metab Dispos. – 2013. – Vol. 41. – N 2.– P. 406–413.135. Cytochrome p450 systems — Biological variations of electron transportchains / F. Hannemann [et al.] // Biochim. Biophys. Acta. – 2007.
– Vol. 1770. –P. 330–344.136. Cytochrome P450: Structure, Mechanism, and Biochemistry / ed.P. R. Ortiz de Montellano. – 3rd edition. – New York: Kluwer Academic/PlenumPublishers, 2005. – 698 p.137. Cytoxrome P450 Substrate Specifities, Substrate structural Templates andEnzyme Active Site Geometries / D.
F. V. Lewis [et al.] // Drug Metabol Drug Interact.– 1999. – Vol. 15. – N 1. – P. 1–51.207138. Dapkunas, J. Probabilistic prediction of the human CYP3A4 and CYP2D6metabolism sites / J. Dapkunas, A. Sazonovas, P. Japertas. Chem Biodivers. – 2009. –Vol. 6. – N 11. – P.
2101–2106.139. Davies, M. J. Protein oxidation and peroxidation / M. J. Davies // Biochem.J. – 2016. – Vol. 473. – N7 – P. 805–825.140. Denisov, I. G. Spectroscopic features of cytochrome P450 reactionintermediates / I. G. Denisov, S. G. Sligar // Archives of Biochemistry and Biophysics.– 2011. – Vol. 507. – N 1. – P. 26–35.141. De Wildt, S. N. 13C-erythromycin breath test as a noninvasive measure ofCYP3A activity in newborn infants: a pilot study / S. N. De Wildt, M. J. Berns,J. N.
van den Anker // Ther Drug Monit. – 2007. – Vol. 29. – N 2. – P. 225–230.142. Di Nardo, G. Optimization of the bacterial cytochrome P450 BM3 systemfor the production of human drug metabolites / G. Di Nardo, G. Gilardi // Int J Mol Sci.– 2012. – Vol. 13. – N 12. – P. 15901–15924.143. Diclofenac and its derivatives as tools for studying human cytochromonesP450 active sites: particular efficiency and regioselectivity of P450 2Cs // A. Mancy [etal.] // Biochemistry.
– 1999. – Vol. 38. – N 43. – P. 14264–14270.144. Differential mechanisms of cytochrome P450 inhibition and activation byalpha-naphthoflavone / A. P. Koley [et al.] // J Biol Chem. – 1997. – Vol. 272. –P. 3149–3152.145. Dihydrolipoic acid maintains ubiquinone in the antioxidant active form bytwo-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone /A. V.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
